Understanding the Market | GIANT BIOGENE rises over 5% again, with impressive GMV growth for KefuMei and KeLiJin online, the company raises its 2024 performance guidance
GIANT BIOGENE rose over 5% again, as of the time of publication, it increased by 4.87%, reporting HKD 57.05, with a trading volume of HKD 44.0996 million. According to news, data from Magic Mirror shows that the GMV growth rate of GIANT BIOGENE's KefuMei brand beauty and skincare products in the Tmall and Taobao channels will reach 42% in 2024, ranking second in the Maotao channel, second only to Ruyi. CMB International pointed out that by the end of 2024, the online GMV growth of KefuMei and KeliJin will be impressive. The company has raised its performance guidance for 2024, expecting revenue growth of over 50% and a net profit attributable to shareholders growth of around 40%. Citigroup also stated that it expects GIANT BIOGENE's revenue in 2024 to increase by 52% year-on-year, and net profit to increase by 40%, consistent with management's guidance. At the same time, it is expected that net profit will grow by 27% and 21% in 2025-2026, benefiting from revenue growth of 30% and 26%, respectively. Therefore, considering the slight dilution of equity after the share placement in April 2024, Citigroup expects the group's three-year net profit compound annual growth rate to be 29%, and the compound annual growth rate of earnings per share to be 28%
According to the Zhitong Finance APP, GIANT BIOGENE (02367) has risen over 5% again, and as of the time of writing, it is up 4.87%, priced at HKD 57.05, with a transaction volume of HKD 44.0996 million.
In terms of news, data from Magic Mirror shows that the GMV growth rate of the beauty and skincare products under the 可复美 brand of GIANT BIOGENE is as high as 42% in the Tmall and Taobao channels for 2024, ranking second in the cat-and-tao channels, second only to 儒意. CMB International pointed out that by the end of 2024, the online GMV growth of 可复美 and 可丽金 will be impressive. The company has raised its performance guidance for 2024, expecting revenue growth of over 50% and a net profit attributable to the parent company to grow by about 40%.
Citigroup also stated that it expects GIANT BIOGENE's revenue in 2024 to increase by 52% year-on-year, with net profit increasing by 40%, consistent with management's guidance. At the same time, it is expected that net profit will grow by 27% and 21% in 2025 and 2026, respectively, benefiting from revenue growth of 30% and 26%. Therefore, considering the slight dilution of equity after the April 2024 placement, Citigroup expects the group's three-year compound annual growth rate of net profit to be 29%, and the compound annual growth rate of earnings per share to be 28%